Protalex, Inc. Announces Completion of Dosing Patients in 4th Cohort of Its Phase 1b Dose Escalation Study of PRTX-100 in Patients With Active Rheumatoid Arthritis

SUMMIT, N.J., Jan. 17, 2012 (GLOBE NEWSWIRE) -- Protalex, Inc. (OTCBB:PRTX), a clinical stage biopharmaceutical company which is engaged in developing a class of drugs for treating autoimmune and inflammatory diseases today announced it has completed patient dosing in the 4th cohort of Part A of its ongoing multicenter Phase 1b dose escalation clinical study of PRTX-100 in adult patients with active rheumatoid arthritis (RA) being conducted in South Africa. A total of 37 patients were randomized in 4 dose escalating cohorts.